Bosh sahifaONC ⢠NASDAQ
add
BeOne Medicines AG
275,28Â $
Seans yopilganidan keyin:(0,00%)0,00
275,28Â $
Yopilgan:20-mar, 16:11:44 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
282,72Â $
Kunlik diapazon
274,97Â $ - 285,50Â $
Yillik diapazon
196,53Â $ - 385,22Â $
Bozor kapitalizatsiyasi
34,57Â mlrd USD
OÊğrtacha hajm
263,96Â ming
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 1,50Â mlrd | 32,84% |
Joriy xarajat | 1,17Â mlrd | 11,85% |
Sof foyda | 66,50Â mln | 143,79% |
Sof foyda marjasi | 4,44 | 132,96% |
Har bir ulushga tushum | 0,58 | â |
EBITDA | 219,47Â mln | 822,86% |
Amaldagi soliq stavkasi | 55,44% | â |
Balans
Jami aktivlari
Jami passivlari
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 4,55Â mlrd | 73,08% |
Jami aktivlari | 8,19Â mlrd | 38,30% |
Jami passivlari | 3,83Â mlrd | 47,85% |
Umumiy kapital | 4,36Â mlrd | â |
Tarqatilgan aksiyalar | 110,94Â mln | â |
Narxi/balansdagi bahosi | 7,19 | â |
Aktivlardan daromad | 5,85% | â |
Kapitaldan daromad | 8,73% | â |
Pul aylanmasi
Naqd pulning sof oÊğzgarishi
| (USD) | dek, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 66,50Â mln | 143,79% |
Operatsiyalardan naqd pul | 417,35Â mln | 455,28% |
Sarmoyadan naqd pul | -38,34Â mln | 59,05% |
Moliyadan naqd pul | 96,93Â mln | 2Â 243,07% |
Naqd pulning sof oÊğzgarishi | 499,10Â mln | 768,32% |
BoÊğsh pul | 385,44Â mln | 9Â 151,22% |
Haqida
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024 the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Tashkil etilgan
28-okt, 2010
Xodimlar soni
12Â 000
